Erythropoietin and iron

Clinical Nephrology

Volumn 47, Issue 3, 1997, Pages 141-157

  Sunder Plassmann, G ^a,b   Horl W H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Erythropoietin; Ferritin; Hypochromic red cells; Iron; Renal failure; Transferrin saturation; Zinc protoporphyrin

Indexed keywords

FERRITIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

CANCER; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; ERYTHROCYTE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; ORAL DRUG ADMINISTRATION; PERITONEAL DIALYSIS; REVIEW;

EID: 1842336289     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (246)

1. Alfurayh O, Sobh M, Barri Y, Qunibi W, Taher S 1992 Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis. Nephrol Dial Transplant 7: 939-943
2. Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R 1982 Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1: 652-655
3. Allegra V, Mengozzi G, Vasile A 1991 Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron 57: 175-182
4. Allen DA, Macdougall IC, Raine AEG 1995 Interferon-γ mediates resistance to erythropoietin in uremic patients with inflammatory disease. J Am Soc Nephrol 6: 517 (abstract)
5. Almond MK, Tailor D, Kelsey SM, Cunningham J 1994a Treatment of erythropoietin resistance with cyclosporin. Lancet 343: 916-917 (letter)
6. Almond MK, Tailor D Marsh FP, Raftery MJ, Cunningham J 1994b Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme. Nephrol Dial Transplant 9: 270-273
7. Altmann P, Plowman D, Marsh F, Cunningham J 1988 Aluminium chelation therapy in dialysis patients: evidence for inhibition of haemoglobin synthesis by low levels of aluminium. Lancet 1: 1012-1015
8. Anastassiades EG, Howarth D, Howarth J, Shanks D, Waters HM, Hyde K, Geary CG, Liu Yin JA, Gokal R 1993 Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 8: 846-853
9. Aschero A, Willett WC 1994 Are body iron stores related to the risk of coronary heart disease? N Engl J Med 330: 1152-1153 (editorial)
10. Baldus M, Salopek S, Möller M, Schliesser J, Klooker P, Reddig J, Gansen U, Brass H 1996 Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic hemodialysis patients. Nephrol Dial Transplant 11: 486-491
11. Barany P, Clyne N, Hylander B, Johansson AC, Simonsen O, Larsson K, Frisenette-Fich C, Svensson B, Helmers C 1995 Subcutaneous epoetin beta in renal anemia: an open multicenter dose titration study of patients on continuous peritoneal dialysis. Pent Dial Int 75: 54-60
12. Barbour GL 1979 Effect of parathyroidectomy on anemia in chronic renal failure. Arch Intern Med 139: 889-891
13. Barosi G, Cazzola M, Stefanelli M, Perugini S 1978 Erythropoiesis and iron kinetics. Br J Haematol 40: 503-504
14. Barosi G, Cazzola M, Berzuini C, Quaglini S, Stefanelli M 1985 Classification of anaemia on the basis of ferrokinetic parameters. Br J Haematol 61: 357-370
15. Barth RH, Aboul-Magd A, Goldwasser P 1995 Response to iron dextran therapy is not precluded by high serum ferritin (Ferr). J Am Soc Nephrol 6: 519 (abstract)
16. Beamish MR, Davies AG, Eakins JD, Jacobs A, Trevett D 1971 The measurement of reticuloendothelial iron release using iron-dextran. Br J Haematol 21: 617-622
17. Beaumont C, Leneuve P, Devaux I, Scoazec JY, Berthier M, Loiseau MN, Grandchamp B, Bonneau D 1995 Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. Nature Genetics 77: 444-446
18. Becker BN, Koury MJ 1993 Resistance to erythropoietin in dialysis patients: factors that decrease erythropoietin responsiveness. Dial Transplant 22: 686-692
19. Beguin Y, Stray SM, Cazzola M, Huebers HA, Finch CA 1988 Ferrokinetic measurement of erythropoiesis. Acta Haematol 79. 121-126
20. Beguin Y, Loo M, R'Zik S, Sautais B, Lejeune F, Rorive G, Fillet G 1995 Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin. Brit J Haematol 89: 17-23
21. Bell JD, Kincaid WR, Morgan RG, Bunce H, Alperin JB, Sarles HE, Remmers AR Jr 1980 Serum ferritin assay and bone-marrow iron stores in patients on maintenance haemodialysis. Kidney Int 17: 237-241
22. Bergmann M, Grütynacher P, Heuser J, Kaltwasser JP 1990 Iron metabolism under rEPO therapy in patients on maintenance hemodialysis. Int J Artif Organs 73: 109-112
23. Besarab A 1993 Optimizing epoietin therapy in end-stage renal disease: the case for subcutaneous administration. Am J Kidney Dis 22(Suppl 1): 13-22
24. Besarab A, Ross RP, Nasca TJ 1995 The use of recombinant human erythropoietin in predialysis patients. Curr Opin Nephrol Hypertens 4: 155-161
25. Bia MJ, Cooper K, Schnall S, Duffy T, Hendler E, Malluche H, Solomon L 1989 Aluminium induced anemia: pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int 36: 852-858
26. Biesma DH, Van de Wiel A, Beguin Y, Kraaijenhagen RJ, Marx JJ 1995 Post-operative erythropoiesis is limited by the inflammatory effect of surgery on iron metabolism. Eur J Clin Invest 25: 383-389
27. Birgegard G, Hällgren R, Killander A, Stromberg A, Venge P, Wide L 1978 Serum ferritin during infection. A longitudinal study. Scand J Haematol 21: 333-340
28. Birgegard G, Hällgren R, Killander A, Venge P, Wide L 1979 Serum ferritin during infection. A longitudinal study in renal transplant patients. Acta Med Scand 205: 641-645
29. Birgegard G 1989 Erythropoiesis and inflammation. Contrib Nephrol 76:330-341
30. Blake DR, Winyard P, Lunec J, Williams A, Good PA, Crewes SJ, Gutteridge JMC, Rowley D, Halliwell B, Cornish A, Hider RC 1985 Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 56: 345-355
31. Blumberg AB, Marti HRM, Graber CG 1983 Serum ferritin and bone marrow iron in patients undergoing continuous ambulatory peritoneal dialysis. JAMA 250: 3317-3319
32. Boelaen JR, Cantinieaux BF, Hariga CF, Fondu PG 1990 Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 5: 504-507
33. Borawski J, Mazerska M, Pawlak K, Mysliwiec M 1995 Ketanserin lowers erythropoietin concentration in hemodialyzed patients treated with the hormone. J Cardiovasc Pharmacol 26: 621-626
34. Braun J, Hammerschmidt M, Schreiber M, Heidler R, Hörl WH 1996 Is zinc protoporphyrin an indicator of iron deficient erythropoiesis in maintenance hemodialysis patients? Nephrol Dial Transplant 11: 492-197
35. Braun J, Lindner K, Schreiber M, Heidler RA, Hörl WH 1997 The percentage of hypochromic red blood cells and the increase of serum ferritin as predictors of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant, in press
36. Brozovich B, Cattell WR, Cottrall MF, Gwyther MM, McMillan JM, Malpas JS, Salsbury A, Trott NG 1971 Iron metabolism in patients undergoing regular dialysis therapy. Br Med J 1: 695-698
37. Brunati C, Piperno A, Guastoni C, Perrino ML, Civali G, Teatini U, Perego A, Fiorelli G, Minetti L 1990 Erythrocyte ferritin in patients on chronic hemodialysis treatment. Nephron 54: 219-223
38. Burns DL, Mascioli EA, Bistrian BR 1995 Parenteral iron dextran therapy: a review. Nutrition 11: 163-168
39. Cantinieaux B, Boelaen J. Hariga C, Fondu P 1988 Impaired neutrophil defense against Yersinia enterocolitica in patients with iron overload who are undergoing dialysis. J Lab Clin Med 111: 524-528
40. Cartwright GE, Lee GR 1971 The anaemia of chronic disorders. Br J Haematol 21: 147-152
41. Cavill I 1982 Diagnostic methods. Clin Haematol 11: 259-273
42. Cazzola M, Huebers HA, Sayers M H, MacPhail AP, Eng M, Finch CA 1985 Transferrin saturation, plasma iron turnover and transferrin uptake in normal humans. Blood 66: 935-939
43. Cazzola M, Pootrakul P, Huebers HA, Eng M, Eschbach J, Finch CA 1987 Erythroid marrow function in anemic patients. Blood 69: 296-301
44. Cofan F, Bonal J, Castellote E, Caralps A 1993 Vasculitis in haemodialysis: a new form of resistance to erythropoietin. Nephrol Dial Transplant 8: 569-570 (letter)
45. Combe C, Delmas-Beauvieux MC, Peuchant E, de Precigout V, Carhonneau MA, Clerc M, Aparicio M 1993 Antioxidant enzymes and erythropoietin therapy in haemodialysed patients supplemented or not with iron. Nephrol Dial Transplant 8: 956-957 (abstract)
46. Conlon PJ, O'Neill S, O'Neill G, Kelly F, Donohoe J 1994 Chronic occult intraalveolar hemorrhage: a rare cause of failure to respond to erythropoietin. Clin Nephrol 41: 83-85
47. Cook JD, Marsaglia G, Eschbach JW, Funk DD, Finch CA 1970 Ferrokinetics: a biologic model for plasma iron exchange in man. J Clin Invest 49: 197-205
48. Cook JD, Skikne BS, Lynch SR, Reusser ME 1986 Estimates of iron sufficiency in the US population. Blood 68: 726-731
49. Cook JD 1995 Iron supplementation: is less better? Lancet 346: 587 (commentary)
50. Cotes PM, Pippard MJ, Reid CDL, Winearls CG, Oliver DO, Royston JP 1989 Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Q J Med70: 113-137
51. Cozma G, Cozma MC, Mattes V 1992 Beneficial effect of recombinant human erythropoietin in beta thalassaemia patients on dialysis. Nephrol Dial Transplant 7: 82-83 (letter)
52. Danielson B, Geisser P, Schneider W 1996 Iron therapy with special emphasis on intravenous administration. Vifor Inc. St. Gallen, p 27
53. Davies AG, Beamish MR, Jacobs A 1971 Utilization of iron dextran. Br J Med 1: 146-147
54. Dainiak N, Kulkarni V, Howard D, Kalmanti M, Dewey MC, Hoffmann R 1983 Mechanisms of abnormal erythropoiesis in malignancy. Cancer 57: 1101-1106
55. De Marchi S, Cecchin E, Franceschin A, Sepiacci G, Bartoli E 1991 Does serum ferritin (sFe) overestimate iron stores in hemodialysis (HD) patients treated with erythropoietin (rHuEPO)? Usefulness of erythrocyte zinc protoporphyrin (ZnPP) measurements. EDTA Congress. Rimini. Abstract book: p 150
56. De Marchi S, Cecchin E 1991 Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin. Clin Sci Colch 81: 113-121
57. Desforges JF 1970 Anemia in uremia. Arch Intern Med 726: 808-811
58. Dhondt AW, Vanholder RC, Kingoir SMG 1995 Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. Nephrol Dial Transplant 10: 2107-2109
59. Diaz-Tejeiro R, Maduell F, Diez J, Esparza N, Errasti P, Purroy A 1989 Red cell distribution width: a method that improves detection of iron deficiency in chronic hemodialysis patients. Nephron 53: 379-380
60. Domoto DT, Martin KJ 1992 Failure of CAPD patients to respond to an oral iron absorption test. Adv Perit Dial 8: 102-104
61. Donnelly SM, AU MA, Churchill DN 1990 Bioavailability of iron in hemodialysis patients treated with erythropoietin: evidence for the inhibitory role of aluminium. Am J Kidney Dis 16: 447-451
62. Donnelly SM, Posen G A, AU MA 1991 Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med 14: 271-276
63. Dunea G, Swagel MA, Bodiwala U, Arruda JA 1994 Intradialytic oral iron therapy. Im J Artif Organs 17: 261-264
64. Edlinger R, Patruta SI, S under-Plassmann G, Hörl WH 1997 Neutrophil impairment as a result of iron therapy in hemodialysis patients with functional iron deficiency. Submitted
65. Edwards MS, Pegrum GD, Curtis JR 1970 Iron therapy in patients on maintenance haemodialysis. Lancet 2: 491-493
66. Erslev AJ 1991 Erythropoietin. N Engl J Med 324: 1339-1344
67. Eschbach JW, Funk D, Adamson J, Kuhn I, Scribner BH, Finch CA 1967 Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 276: 653-658
68. Eschbach JW, Cook JD, Finch CA 1970 Iron absorption in chronic renal disease. Clin Sci 38: 191-196
69. Eschbach JW, Cook JD, Scribner BH, Finch CA 1977 Iron balance in hemodialysis patients. Ann Intern Med 87: 710-713
70. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW 1987 Correction of the anemia of end stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73-78
71. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW 1989a Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321: 158-163
72. Eschbach JW, Abdulhadi MB, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR et al. 1989b Recombinant human erythropoietin in anemic patients with end stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111: 992-1000
73. Eschbach JW, Haley NR, Egrie JC, Adamson JW 1992 A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int 42: 407-416
74. Eschbach JW, Glenny R, Robertson T, Guthrie M, Rader B, Evans R, Chandler W, Davidson R, Easterling T, Denney J, Schneider G 1993 Normalizing the hematocrit (HCT) in hemodialysis patients (HDP) with EPO improves quality of life (Q/L) and is safe. J Am Soc Nephrol 4: 425 (abstract)
75. Eschbach JW 1995 The future of r-HuEPO. Nephrol Dial Transplant 70:96-109 (suppl)
76. Evers J 1993 Parenteral iron during hemodialysis. Nephron 64: 490 (letter)
77. Faller B, Slingeneyer A, Waller M, Michel C, Grützmacher P, Müller HP. Barany P, Grabensee B, Issad B, Schmitt H, MeislF 1993 Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study. Clin Nephrol 40: 168-175
78. Feelders RA, Vreugdenhil G 1992 Effects of erythropoietin and iron chelators on iron metabolism in anaemia. Erythropoiesis 3: 80-89
79. Fishbane S, Frei GL, Maesaka J 1995 Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41-46
80. Fishbane S, Lynn RI 1995a The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 44: 238-240
81. Fishbane S, Lynn RI 1995b The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis 25: 426-432
82. Fishbane S, Maesaka J 1995 Factors predictive of suboptimal iron stores in hemodialysis (HD) patients with normal iron indices. J Am Soc Nephrol 6: 529 (abstract)
83. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK 1996 The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7: 2654-2657
84. Flament J, Goldman M, Waterlot Y, Dupont E, Wybran J, Vanherweghem JL 1986 Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clin Nephrol 25: 227-230
85. Fleming LW, Stewart WK, Parratt D 1992 Dextran antibodies, complement conversion and circulating immune complexes after intravenous iron dextran therapy in dialysed patients. Nephrol Dial Transplant 7: 35-39
86. Fourtounas C, Kavadias O, Tsouknikas Z, Barboutis K 1993 Iron deficiency in haemodialysis patients during erythropoietin therapy: is it predictable? Nephrol Dial Transplant 8: 957-958 (abstract)
87. Fourtounas C, Kavadias D, Tsouknikas J, Barboutis K 1994 Reduction of maintenance dose of erythropoietin by monthly prediction of iron deficiency. Nephrol Dial Transplant 9: 1030 (abstract)
88. Garrett S, Worwood M 1994 Zinc protoporphyrin and iron deficient erythropoiesis. Acta Haematol 91: 21-25
89. Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C 1995 Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 10 (Suppl 6): 44-47
90. Geisser P, Baer M, Schaub E 1992 Structure/histotoxicity relationship of parenteral iron preparations. Arzneim-Forsch/Drug Res 42: 1439-1452
91. Goch J, Birgegard G, Danielson BG, Wikstrom B 1995 Treatment of erythropoietin-resistant anemia with desferrioxamine in patients on hemofiltration. Eur J Haematol 55: 73-77
92. Gokal R, Millard PR, Weatherall DJ, Callender STE. Ledingham JGG, Oliver DO 1979 Iron metabolism in haemodialysis patients. A study of the management of iron therapy and overload. Q J Med 45:369-391
93. Golan E, Radnay J, Goldmann J, Bernheim J, Rathaus M 1994 Relationship between transferrin saturation index and red cell size and haemoglobin content in haemodialysis patients. Nephrol Dial Transplant 9: 1030-1031 (abstract)
94. Goldman M, Vanherweghem JL 1987 Multiple blood transfusions and iron overload in patients receiving haemodialysis. Nephrol Dial Transplant 2: 205-207
95. Granolleras C, Oules R, Shaldon S, Pollock M, Baldamus CA, Nonnast-Daniel B, Koch KM 1991 Benefit of continuous i.v. iron with erythropoietin therapy in hemodialysis patients. Nephrol Dial Transplant 6: 824 (abstract)
96. Grützmacher P. Ehmer B, Messinger D, Kulbe KD, ScigalleP 1989 Effect of aluminium overload on the bone marrow response to recombinant human erythropoietin. Contrib Nephrol 76: 315-323
97. Grützmacher P, Ehmer B, Limhach J, Messinger D, Kulbe KD, Scigalla P 1990 Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparatyroidism. Blood Punf 8: 279-284
98. Grützmacher P, Tsobanelis T, Roth P, Werner E, Vlachojannis J, Kaltwasser J, Kurz P, Scheuermann EH, Schoeppe W 1992 Effect of recombinant human erythropoietin on iron balance in maintenance haemodialysis: theoretical considerations, clinical experience and consequences. Clin Nephrol 38 (Suppl 1): 92-97
99. Hakim RM, Stivelman, JC, Schulman G, Fosburg M, Wolfe L, Imber MJ, Lazarus JM 1987 Iron overload and mobilization in long term hemodialysis patients. Am J Kidney Dis 10: 293-299
100. Harnstra RD, Block MH, Schocket AL 1980 Intravenous iron dextran in clinical medicine. JAMA 243: 1726-1731
101. Hastka J, Lasserre JJ, Schwarzbeck A, Hehlmann R, Strauch M 1991 Zinkprotoporphyrin als Alternative zu Ferritin bei Steuerung der Eisensubstitution Erythropoietin-bedürftiger Dialysepatienten. Nieren Hochdruckkrankh 20: 697-700
102. Hastka J, Lasserre JJ, Schwarzbeck A, Hehlmann R 1994 Central role of zinc protoporphyrin in staging iron deficiency. Clin Chem 40: 768-773
103. Hatton RC, Portales IT, Finlay A, Ross EA 1995 Removal of iron dextran by hemodialysis: an in vitro study. Am J Kidney Dis 26: 327-330
104. Hazard JT, Dryadale JW 1977 Ferritinaemia in cancer. Nature 265: 755-756 (letter)
105. Heinrich HC 1986 Bioverfügbarkeit und therapeutischer Wert oraler Eisen-(II)- und Eisen-(III)-Präparate. Deutsch Apoth Zeitung 14: 681-690
106. Henderson PA, Hillman RS 1969 Characteristics of iron dextran utilization in man. Blood 34: 357-375
107. Hocken AG, Marwah PK 1971 latrogenic contribution to anaemia of chronic renal failure. Lancet I: 164-165
108. Holley JL, Nolan TA, Piraino B 1992 Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease. Clin Nephrol 37: 145-147
109. Hörl WH, Cavill I, Cove-Smith R, Eschbach J, Macdougall IC. Salmonson T, Schaefer RM, Sunder-Plassmann G 1995 How to get the best out of r-HuEPO? Nephrol Dial Transplant 10 (Suppl 2): 92-95
110. Hörl WH, Cavill I, Macdougall IC, Schaefer RM, Sunde r-P lassmann G 1996 How to diagnose and correct iron deficiency during r-huEPO therapy - a consensus report. Nephrol Dial Transplant 11: 246-250
111. Hotta T, Ogawa H, Saito A, Ito A 1991 Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure. Int J Haematol 54: 195-200
112. Huff RL Hennessy TGt Austin RE, Garcia JF, Kobens BM, Lawrence JH 1950 Plasma and red cell iron turnover in normal subjects and in patients having various hematopoietic disorders. J Clin Invest 29: 1041-1052
113. Hughes RT, Cotes PM, Pippard MJ, Stevens JM, Oliver DO, Winearls CG, Royston JP 1990 Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment. Br J Haematol 75: 268-273
114. Hughes RT, Smith T, Hesp R, Hulme B, Dukes DC, Bending MB, Pearson J, Raja KB, Cotes PM, Pippard MJ 1992 Regulation of iron absorption in iron loaded subjects with end stage renal disease: effects of treatment with recombinant human erythropoietin and reduction of iron stores. Br J Haematol 82: 445-454
115. Ifudu O, Feldman J, Friedman EA 1996 The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 334: 420-425
116. Ikeda Y, Sakemi T, Ohtsuka Y, Kuwahara M, Fujisaki N 1997 Drugrelated responsiveness to recombinant human erythropoietin therapy in three patients with end-stage renal disease. Nephrol Dial Transplant (submitted)
117. Johnson CA, Rosowski E, Zimmerman SW 1992 A prospective openlabel study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN. Adv Pent Dial 8: 444-447
118. Kavadias D, Fourtounas C, Tsouchnikas J, Vlachonasios T, Barboutis K 1995 Reduction of the cost of erythropoietin therapy by coadministration of L-carnitine in hemodialysis patients. Nephrol Dial Transplant 10: 1047 (abstract)
119. Kieffer K 1995 Eisenüberladung und oxidativer Streß. Forsch Komplernentärmed 2: 259-267
120. Klausner RD, Rouault TA, Harford JB 1993 Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 72: 19-28
121. Kleiner MJ, Van Wyck DB, Kaupke CJ, Kirlin LF 1995 The role of iron and other factors in patients unresponsive to erythropoietin therapy. Semin Dial 8: 29-34
122. Klemm A, Sperschneider H, Lauterbach H, Stein G 1994 Is folate and vitamin B12 supplementation necessary in chronic hemodialysis patients with EPO treatment? Clin Nephrol 42: 343-345 (letter)
123. Knekt P, Reunanen A, Takkunen H, Aromaa A, Heliovaara M, Hakulinen T 1994 Body iron stores and risk of cancer. Int J Cancer 56: 379-382
124. Koch KM, Patyna WD, Shaldon S, Werner E 1974 Anemia of the regular hemodialysis patient and its treatment. Nephron 12: 405-419
125. Koch KM, Bechstein PB, Fassbinder W, Kaltwasser P, Schoeppe W, Werner E 1976 Occult blood loss and iron balance in chronic renal failure. Proc EDTA 12: 362-369
126. KonijnAM, Hershko C 1977 Ferritin synthesis in inflammation: pathogenesis of impaired iron release. Br J Haematol 37: 7-16
127. Kooistra MP, van Es A, Struyvenberg A, Marx JJM 199la Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 79: 634-639
128. Kooistra MP, Struyvenberg A, van Es A 1991b The response to recombinant human erythropoietin in patients with the anaemia of endstage renal disease is correlated with serum carnitine levels. Nephron 57: 127-128 (letter)
129. Kooistra MP, van Es A, Struyvenberg A, Marx JJM 1995 Low iron absorption in erythropoietin-treated hemodialysis patients. J Am Soc Nephrol 6: 543 (abstract)
130. Koury MJ 1993 Investigating erythropoietin resistance. N Engl J Med 328: 205-206 (editorial)
131. Kumpf VJ, Holland EG 1990 Parenteral iron dextran therapy. DICP 24: 162-166
132. Lai KN, Wong KC, Li PKT, Lui SF 1992 Use of recombinant erythropoietin in thalassemic patients on dialysis. Am J Kidney Dis 19: 239-245
133. Lawson DH, Boddy K, Linton AL, Will G 1971 Iron losses in dialysis patients. Lancet 2: 312 (letter)
134. Lazarus JM, Hakim RM, Newell J 1990 Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients. Am J Kidney Dis 16: 101-108
135. Levin NW, Lazarus JM, Nissenson AR 1993 National cooperative rHu-erythropoietin study in patients with chronic renal failurean interim report. Am J Kidney Dis 22 (Suppl 1): 3-12
136. Lin JL, Lim PS, Leu ML 1995 Relationship of body iron status and serum aluminium in chronic renal insufficiency patients not taking any aluminium-containing drugs. Am J Nephrol 15: 118-122
137. Lindsay RM, Burton JA, Edward N, Dargie HJ, Prentice CRM, Kennedy AC 1973 Dialyzer blood loss. Clin Nephrol 1: 29-34
138. Lipschitz DA, Cook JD, Finch CA 1974 A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 290: 1213-1216
139. Low CL, Bailie GR, Eisele G 1996 Erythropoietin resistance: a quantitative definition. Nephrol Dial Transplant, in press
140. Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U 1990 Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322: 1693-1699
141. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J 1994 Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84: 1056-1063
142. Lustbader ED, Hann HW, Blumberg BS 1983 Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 220: 423-425
143. Lynn KL, Mitchell TR, Shepperd J 1981 Red cell indices and iron stores in patients undergoing haemodialysis. Br Med J Clin Res Ed 282: 2096
144. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD 1989 Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 299: 157-158
145. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD 1990a Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm. Br Med J 300: 655-659
146. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD 1990b Recombinant human erythropoietin in the treatment of renal anaemia: an update. Nefrologia 10 (Suppl 2): 23-32
147. Macdougall IC, Cavill I, Hulme B, Brain B, McGregor E, McKay P, Sanders E, Coles GA, Williams JD 1992a Detection of functional iron deficiency during erythropoietin treatment: a new approach. Br Med J 304: 225-226
148. Macdougall IC, Coles GA, Williams JD 1992b Inhibition of a response to erythropoietin in the presence of infection or malignancy. Erythropoiesis 3: 29-30
149. Macdougall IC, Jones EA, Evans W, Cavill I, Coles GA, Williams JD 1993a Measurement of occult gastrointestinal blood loss in haemodialysis patients on erythropoietin. Nephrol Dial Transplant 8: 959-960 (abstract)
150. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LRI, Raine AEG 1996 A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699
151. Macdougall IC, Alien DA, Tucker B, Baker LRI, Raine AEG 1993c Serum interleukin-6 levels are a useful indicator of marrow suppression in patients with resistance to erythropoietin due to inflammatory disease. J Am Soc Nephrol 4: 428 (abstract)
152. Macdougall IC 1994 Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens 3: 620-625
153. Macdougall IC 1995a Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 10: 607-614
154. Macdougall IC 1995b How to get the best out of r-HuEPO. Nephrol Dial Transplant 10 (Suppl 2): 85-91
155. Macdougall IC 1995c Poor response to erythropoietin. Should be fully investigated and treated. Br Med J 310: 1424-1425
156. Magana L, Dhar SK, Smith EC, Martinet C 1984 Iron absorption and utilization in maintenance hemodialysis patients: oral and intravenous routes. Mount Sinai J Med 51: 180-183
157. Magnusson MK, Sigfusson N, Sigvaldason H, Johannesson GM, Magnusson S, Thorgeirsson G 1994 Low iron-binding capacity as a risk factor for myocardial infarction. Circulation 89: 102-108
158. Marchasin S, Wallerstein RO 1964 The treatment of iron-deficiency anemia with intravenous iron dextran. Blood 23: 354-358
159. McGonigle RJS, Parsons V 1985 Aluminium-induced anaemia in hemodialysis patients. Nephron 39: 1-9
160. Means RT, Krantz SB 1992 Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80: 1639-1647
161. Meytes D, Bogin E, Ma A, Dukes PP, Massry SG 1981 Effects of parathyroid hormone on erythropoiesis. J Clin Invest 67: 1263-1269
162. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL 1990 Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322: 1689-1692
163. Milman N 1976 Iron therapy in patients undergoing maintenance haemodialysis. Acta Med Scand 200: 315-319
164. Milman N, Christensen T, Bartels U, Larsen L 1979 Iron absorption and iron status in patients with chronic uremia on regular peritoneal dialysis. Acta Med Scand 205: 629-635
165. Mladenovic J 1988 Aluminium inhibits erythropoiesis in vitro. J Clin Invest 81: 1661-1665
166. Muirhead N, Hodsman AB 1990 Occult infection and resistance of anaemia to rHuEPO therapy in renal failure. Nephrol Dial Transplant 5: 232-234
167. Muirhead N, Hodsman AB, Hollomby DJ, Cordy PE 1991 The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 6: 342-345
168. Muirhead N 1991 Factors affecting the response to erythropoietin in chronic renal failure. Semin Dial 4: 5-8
169. Muirhead N, Cattran DC, Zaltzman J, Jindal K, First MR, Boucher A, Keown PA, Munch LC, Wong C 1994 Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol 5: 1216-1222
170. Muirhead N, Bargman J, Burgess E, Jindal KK, Levin A, Nolin L, Parfrey P 1995 Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 26(Suppl 1):S1-S24
171. Najean Y, Moynot A, Deschryver F, Zins B, Naret C, Jacquot C, Drueke T 1989 Kinetics of erythropoiesis in dialysis patients receiving recombinant erythropoietin treatment. Nephrol Dial Transplant 4:350-355
172. Neff M 1995 Algorithm for the treatment of anemia in ESRD, developed by the Network Forum Quality Assurance Committee USA, revised 4/95
173. Ng YY, Chow MP, Lyou JY, Hu MY, Yung CH, Fan CD, Huang TP 1993 Resistance to erythropoietin: immunohemolytic anemia induced by residual formaldehyde in dialyzers. Am J Kidney Dis 21: 213-216
174. Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, Hamburger R, Mattern W, Schreiber M, Swartz R, Van Stone J, Watson A, Zimmerman S 1995 Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 5: 1517-1529
175. Nyvad O, Danielsen H, Madsen S 1994 Intravenous iron-surcrose complex to reduce epoetin demand in dialysis patients. Lancet 344: 1305-1306 (letter)
176. Ozono Y, Harada T, Taura K, Kawatomi M, Hara K 1994 rHuEPO resistant anaemia in haemodialysis patients. Nephrol Dial Transplant 9: 872-874
177. Page B, Zitouni Z, Zingraff J 1993 Resistance to r-HuEPO and kidney graft rejection in patients on haemodialysis. Nephrol Dial Transplant 8: 961-962 (abstract)
178. Pascual J, Teruel JL, Liano F, Sureda A, Ortuno J 1991 Sodium ferric gluconate complex given intravenously for iron-deficiency in haemodialysis. Clin Nephrol 35: 87 (letter)
179. Pascual J, Teruel JL, Liano F, Sureda A, Ortuno J 1992 Intravenous Fe-gluconate-Na for iron-deficient patients on haemodialysis. Nephron60: 121 (letter)
180. Piazza V, Villa G, Galli F, Segagni S, Bovio G, Poggio F, Picardi L, Salvadeo A 1992 Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis. Nephron 61: 54-57
181. Powe NR, Griffiths RI, Greer JW, Watson AJ, Anderson GF, De Lissovoy G, Herben RJ, Eggers PW, Milam RA, Wtielton PK 1993 Early dosing practices and effectiveness of recombinant human erythropoietin. Kidney Int43: 1125-1133
182. Raja R, Bloom E, Goldstein M, Johnson R 1993 Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population. ASAIO J 39: M578-M580
183. Raja R, Bloom E, Johnson R, Goldstein M 1994 Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency. Adv Peril Dial 10: 135-138
184. Rao OS, Shih MS, Mohini R 1993 Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328: 171-175
185. Reizenstein P 1991 Iron, free radicals and cancer. Med Oncol Tumor Pharmacotherapy 8: 229-233
186. Roger SD, Stewart JH, Harris DCH 199la Desferrioxamine enhances the haemopoietic response to erythropoietin, but adverse events are common. Nephron 58: 33-36
187. Roger SD, Macdougall IC, Thuraisingham RC, Raine AEG 1991b Erythropoietin in anemia of renal failure in sickle cell disease. N Engl J Med 325: 1175-1176 (letter)
188. Rosenberg ME 1992 Role of transferrin measurement in monitoring iron status during recombinant human erythropoietin therapy. Dial Transplant 21: 81-90
189. Rosenlöf K, Gronhagen-Riska C, Sovijarvi A, Honkanen E, Tikkanen I, Ekslrand A, Piirila P, Fyhrquisl F 1989 Beneficial effects of erythropoietin on haematological parameters, aerobic capacity, and body fluid composition in patients on haemodialysis. J Intern Med 226: 311 -317
190. Rosenlöf K', Fyhrquist F. Tenhunen R 1990 Erythropoietin, aluminium, and anaemia in patients on haemodialysis. Lancet 335: 247-249
191. Rosenlöf K, Kivivuori SM, Grönhagen-Riska C, Teppo AM, Slimes MA 1995 Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol 43: 249-255
192. Schaefer RM, Hörl WH, Massry SG 1989 Treatment of renal anemia with recombinant human erythropoietin. Am J Nephrol 9: 353-362
193. Schaefer RM, Schaefer L 1992 Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 3:71-75
194. Schaefer RM, Schaefer L, Heidland A 1994 The hypochromic red cell: a new parameter for the monitoring of iron therapy during rhEPO treatment. Clin Investig 72: B10 (abstract)
195. Schaefer RM, Schaefer L 1995 The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy. J Perinat Med 23: 83-88
196. Schaefer RM 1996 In: Hörl WH, Cavill I, Macdougall IC, Schaefer RM, Sunder-P'lassmann G 1996 How to diagnose and correct iron deficiency during r-huEPO therapy - a consensus report. Nephrol Dial Transplant 11: 246-250
197. Schwanz AB, Kelch B, Terzian L. Prior J, Kim KE, Pequinot E, Kahn SB 1990 One year of rHuEPO therapy prolongs RBC survival and may stabilize RBC membranes despite natural progression of chronic renal failure and need for dialysis. ASAIO Trans 36; M691-696
198. Schwartz AB, Orquiza CS 1995 The effects of recombinant human erythropoietin on mean corpuscular volume in patients with the anemia of chronic renal failure. Clin Nephrol 43: 256-259
199. Sempos CT. Looker AC, Gillum RF, Makuc DM 1994 Body iron stores and the risk of coronary heart disease. N Engl J Med 330: 1119-1124
200. Sepandj F, Jindal K, West M, Hirsch D 1996 Economic appraisal of maintenance parenteral iron administration in treatment of anemia in chronic hemodialysis patients. Nephrol Dial Transplant 11: 319-322
201. Shepherd AM M, Stewart WK, Wormsley KG 1973 Peptic ulceration in chronic renal failure. Lancet 1: 1357-1359
202. Siimes MA, Ronnholm KA, Antikainen M, Holmberg C 1992 Factors limiting the erythropoietin response in rapidly growing infants with congenital nephrosis on peritoneal dialysis regimen after nephrectomy. J Pediatr 120: 44-48
203. Silverberg DS, Slum M, Peer G, Kaplan E, laina A 1996a Intravenous ferric saccharate as an iron supplement in dialysis patients, Nephron72-413-417
204. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M 1996b Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27: 234-238
205. Skikne BS, Cook JD 1992 Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med 120: 746-751
206. Steinberg MH 1991 Erythropoietin for anemia of renal failure in sickle cell disease. N Engl J Med 324: 1369 (letter)
207. Stivelman J, Schulman G, Fosburg M, Lazarus JM, Hakim RM 1989a Kinetics and efficacy of deferoxamine in iron-over loaded hemodialysis patients. Kidney Int 36: 1125-1132
208. Stivelman JC 1989b Resistance to recombinant human erythropoietin therapy: a real clinical entity? Semin Nephrol 9 (Suppl 2): 8-11
209. Strachan J, Fleming L, Dick J, Henderson I, Fraser C, Jones M, McGregor E 1995 Poor response to erythropoietin. Br Med J 311: 633 (letter)
210. Suh H, Wadhwa NK 1992 Iron dextran treatment in peritoneal dialysis patients on erythropoietin. Adv Pent Dial 8: 464-466
211. Sullivan JL 1995 Iron and heart disease: dangers of testing the wrong hypothesis. Circulation 91: 251-252 (letter)
212. Sunder-Plassmann G, Hörl WH 1994 Iron metabolism and iron substitution during erythropoietin therapy. Clin Investig 72: S11-S15
213. Sunder-Plassmann G, Hörl WH 1995 Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10: 2070-2076
214. Sunder-Plassmann G, Hörl WH 1996 Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 11: 1797-1802
215. Sunder-Plassmann G, Spitzauer S, Hörl WH 1997 The dilemma of evaluating iron status in dialysis patients limitations of available diagnostic procedures. Nephrol Dial Transplant, in press
216. Sungur C, Arik N, Yasavul U, Turgan C, Caglar S 1992a Decreased response to human recombinant erythropoietin therapy in pregnancy. Am J Nephrol 12: 390 (letter)
217. Sungur C, Erbas T, Akpolat T, Arik N, Yasavul U, Turgan C, Caglar S 1992b Resistance to human recombinant erythropoietin in hypothyreoidism. Acta Haematol 88: 162 (letter)
218. Sungur C, Sungur A, Akpolat T, Yasavul U, Turgan C, Caglar S 1992c Unresponsiveness to human recombinant erythropoietin in an epileptic dialysis patient secondary to valproic acid toxicity. Ann Pharmacother 26: 1156 (letter)
219. Sungur C, Sungur A, Arik N, Akpolat T, Arinsoy T, Yasavul U, Turgan C, Caglar S 1993 Bone marrow involvement in systemic amyloidosis: another mechanism for erythropoietin resistance. Nephron 63: 232-233 (letter)
220. Sussman HH 1992 Iron in cancer. Pathobiology 60: 2-9
221. Tamura T, Goldenberg KL, Johnston KE, DuBard MB 1995 Effect of smoking on plasma ferritin concentrations in pregnant women. CIinChem 41: 1190-1191
222. Tarng DC, Chen TW, Huang TP 1995 Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 15: 230-237
223. Tayhr J, Mactier RA, Stewart WK, Henderson IS 1990 Effect of erythropoietin on anaemia in patients with myeloma receiving haemodialysis. Br Med J 301: 476-477
224. Tielemans C, Collart F, Wens R, Smeyers-Verbeeke J, van Hooff I, Dratwa M, Verbeelen D 1985 Improvement of anemia with desferrioxamine in haemodialysis patients with aluminium-induced bone disease. Clin Nephrol 24: 237-241
225. Tielemans C, Collart F, Wens K, Smeyers-Verbeeke J, Van Hooff, Dratwa M, Verbeeelen D 1988 Anaemia and aluminium chelation therapy in dialysis patients. Lancet 2: 220 (letter)
226. Tomson CRV, Edmunds ME, Chambers K, Bricknell S, Feehally J, Walls J 1992 Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 7: 817-821
227. Tsobanelis T, Hoppe D, Scigalla P, Grülzmacher P 199la Optimierte Behandlung der renalen Anämie mit kombinierter intravenöser Eisen- und Ultra-low-dose-Erythropoietin-Substitution. NierenHoch dru ckkrankh 20; 454 (abstract)
228. Tsobanelis T, Roth P, Werner E, Weilz-Miesner B, Kurz A, Vlachojannis J, Grützmacher P 1991b Ferro- und erythroki ne tische Untersuchungen des Eisenstoffwechsels und der renalen Anämie unter Substitution mit rekombinantem humanen Erythropoietin. Nieren-Hochdruckkrankh 20: 685-689
229. Tzamaloukas AH 1994 Resistance to erythropoietin in a dialysis patient. Dial Transplant 23: 20 (letter)
230. Van de Vyver FL, Silva FJ, D 'Haese PC, Verbuchen AH, De Broe ME 1987 Aluminium toxicity in dialysis patients. Contrib Nephrol 55: 198-200
231. Van Lenten BJ, Prieve J, Navab M, Hama S, Lus is AJ, Fogelman AM 1995 Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J Clin Invest 95: 2104-2110
232. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA 1989 Iron status in patients receiving erythropoietin for dialysisassociated anemia. Kidney Int 35: 712-716
233. Vlahakos DV, Balodimos C, Papachristopoulos V, Vassilakos P, Hinari E, Vlachojannis JG 1995 Renin-angiotensin system stimulates erythropoietin secretion in chronic hemodialysis patients. Clin Nephrol 43: 53-59
234. Waterht Y, Cantinieaux B, Hariga-Muller C, de Maetelaere-Laurent E, Vanherweghem JL, Fondu P 1985 Impairment of neutrophil phagocytosis in haemodialysed patients - the critical role of iron overload. Br Med J Clin Res Ed 297: 501-504
235. Wafers W, Wellner U, Baldamus CA, Bramsiepe P, Schicha H 1988 Effect of erythropoietin on iron kinetics in patients with endstage renal disease. Contrib Nephrol 66: 156-164
236. Weinberg ED 1984 Iron withholding: A defense against infection and neoplasia. Physiol Rev 64: 65-102
237. Weiss G, Wachter H, Fuchs D 1995 Linkage of cell-mediated immunity to iron metabolism. Immunol Today 16: 495-500
238. Winchester JE, McGinley M, Wahab A, Hall F, Anderson J, Breifel G, Auerbach M 1995 Comparison of 3 iron dextran (ID) infusion methods to correct anemia in erythropoieiin (rHuEPO) treated hemodialysis (HD) patients. J Am Soc Nephrol 6: 591 (abstract)
239. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM 1986 Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1175-1178
240. Winearls CG, Hughes RT, Pippard MJ, Cotes PM 1992 Erythropoietin dose requirement in a patient with HbH disease and renal failure. Nephrol Dial Transplant 7: 1052-1054
241. Wingard RL, Parker RA, Ismail N, Hakim RM 1995 Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25: 433-439
242. Wood JK, Milner PFA, Pathak UN 1968 The metabolism of iron dextran given as a total dose infusion to iron deficient Jamaican subjects. Br J Haematol 14: 119-129
243. Zachee P, Staal GEJ, Rijksen G, De Bock R, Couttenye MM, De Broe ME 1989 Pyruvate kinase deficiency and delayed clinical response to recombinant human erythropoietin treatment. Lancet 1: 1327-1328 (letter)
244. Zachee P, Boogaerts MA, Lins RL, Daelemans R, Henckens M, De Broe ME 1990 Erythropoietin, aluminium, and anaemia in patients on haemodialysis. Lancet 335: 1038-1039 (letter)
245. Zachee P, Chew SL, Daelemans R, Lins RL 1992 Erythropoietin resistance due to vitamin B12 deficiency: Case report and retrospective analysis of B12 levels after erythropoietin treatment. Am J Nephrol 12: 188-191
246. Zanen AL, Adriaansen HJ, van Bommel EFH, Posthuma R, de Jong GMTh 1996 "Oversaturation" of transferrin after intravenous ferric gluconate (Ferrlecit) in haemodialysis patients. Nephrol Dial Transplant 11: 820-824